Superficial urinary bladder carcinoma

This phase III trial tests whether giving the drug Alpha1H directly into the bladder before standard surgery lowers the risk of cancer returning in adults with low- to intermediate-risk non-muscle-invasive bladder cancer. Participants are randomly assigned to receive either six A…

This study tests a healthy eating program that encourages people with early-stage bladder cancer to eat more cruciferous vegetables like broccoli, kale, and cabbage. These veggies contain natural compounds that may help fight cancer cells. Researchers want to see if this diet cha…

This study tests whether adding an experimental treatment (V940) to standard BCG therapy helps people with high-risk non-muscle invasive bladder cancer live longer without their cancer returning. About 308 adults will be randomly assigned to get either V940 plus BCG or BCG alone.…

People with high-grade non-muscle-invasive bladder cancer often receive BCG immunotherapy, but some cancers stop responding. The standard next step is surgery to remove the bladder, which many patients cannot or choose not to have. This trial tests whether radiation to the whole …

This study tests a new drug called MK-3120 for high-risk non-muscle invasive bladder cancer. After standard tumor removal, 45 participants will receive the drug directly into the bladder. The main goals are to check safety and how well people tolerate it, while also looking at tu…

This study tests a new drug called PF-08052667 for adults with a type of bladder cancer that hasn't spread into the muscle layer but is likely to return. The drug is given directly into the bladder, sometimes with other medicines like BCG or sasanlimab. The trial has three parts …

This phase 3 trial tests a gene therapy called nadofaragene firadenovec against simply watching and waiting in people with intermediate-risk non-muscle invasive bladder cancer. The study will enroll 454 participants who have had a tumor removed. The goal is to see if the gene the…

This study tests a new treatment called HS-10566, a gel that delivers the chemotherapy drug gemcitabine directly into the bladder. It is for people with high-risk non-muscle-invasive bladder cancer who cannot or choose not to have their bladder removed. The trial will check if th…

This Phase 2 trial tests a drug called cretostimogene grenadenorepvec in 325 people with high-risk non-muscle-invasive bladder cancer. The drug is a virus that is put directly into the bladder to attack cancer cells. The study looks at how well it works and how safe it is, includ…

This phase 3 trial tests a new drug, TAR-210 (erdafitinib), placed directly into the bladder, against standard chemotherapy for people with a high-risk type of bladder cancer that has come back after BCG treatment. The study includes 220 adults whose tumors have certain FGFR gene…

This study is tracking 150 people with early-stage bladder cancer who are receiving TAR-200, a treatment placed directly into the bladder. Researchers want to see how long it takes for the cancer to come back or get worse in real-world settings, not just in controlled trials. The…

This early-stage trial is testing a new oral drug called LOXO-435, alone or with other cancer medicines, in people with advanced solid tumors that have a specific change in the FGFR3 gene. The study aims to find the right dose and check for safety and early signs of effectiveness…

This study compares different FDA-approved drugs for a type of bladder cancer that hasn't spread into the muscle. About 125 adults whose previous treatment with BCG didn't work will receive either a newer gene therapy or standard drugs. The goal is to see which treatment better p…

This phase II trial is testing an experimental biologic called T3011, given directly into the bladder, for people with high-risk non-muscle-invasive bladder cancer that has not responded to BCG therapy or chemotherapy. The study aims to see if this treatment can shrink or elimina…

This early-stage trial tests a new drug called PPM, which are tiny particles loaded with the chemotherapy drug paclitaxel and coated with a molecule (PLZ4) that helps them target bladder cancer cells. The drug is given directly into the bladder through a catheter once a week for …

This early-stage study tests a new drug called 2141-V11 in people with a type of bladder cancer that hasn't responded to standard therapy. The drug is given directly into the bladder through a catheter or by injection into the tumor. The main goal is to see if it's safe and to fi…

This study tests a new drug called EG-70 (detalimogene) for a type of bladder cancer called non-muscle invasive bladder cancer (NMIBC). The drug is given directly into the bladder through a catheter. The trial includes patients whose cancer did not respond to standard BCG therapy…

This early-stage trial tests a new drug called JL19001, given alone or with standard BCG therapy, in 18 people with high-risk non-muscle invasive bladder cancer. The main goals are to check safety, find the right dose, and see how the body handles the drug. It's a first step to s…

This phase 3 trial tests whether adding the chemotherapy drug gemcitabine to standard BCG therapy can better prevent high-grade bladder cancer from coming back. About 330 people with recurrent non-muscle invasive bladder cancer will receive either BCG alone or BCG plus gemcitabin…

This study tests whether adding an immunotherapy drug (toripalimab) to standard BCG therapy can help people with high-risk bladder cancer avoid bladder removal. About 31 participants will receive the combination after surgery. The main goal is to see if the cancer disappears with…

This study tests whether adding the drug disitamab vedotin to standard BCG therapy can help keep high-risk, early-stage bladder cancer from returning. It includes 182 adults whose cancer has been surgically removed but is at high risk of coming back. Participants will receive eit…

This phase 2 trial tests a two-drug combination (mitomycin-C and gemcitabine) given directly into the bladder for people with high-risk bladder cancer that did not respond to BCG therapy. The study will enroll 82 participants to see if this sequential treatment can prevent cancer…

This study tests a new treatment for people with a high-risk type of bladder cancer that did not get better after standard BCG therapy. The treatment combines two chemotherapy drugs placed directly into the bladder with an immunotherapy drug given through a vein. The goal is to s…

This expanded access program offers a modified tuberculosis vaccine (recombinant BCG) to people with non-muscle invasive bladder cancer who cannot join a clinical trial. The treatment is given directly into the bladder and aims to control the disease. It is only for patients who …

This phase 2 trial is testing whether two chemotherapy drugs, gemcitabine and docetaxel, given directly into the bladder can treat high-risk bladder cancer that did not respond to standard BCG therapy. About 174 adults will receive weekly treatments for 6 weeks, then monthly for …

This early-stage trial is testing a new version of the BCG therapy, made from a genetically modified bacterium, for people with non-muscle invasive bladder cancer (NMIBC) who have not received BCG before. The treatment is given directly into the bladder through a catheter. The st…

This early-stage trial tests a new treatment called PLZ4-coated paclitaxel-loaded micelles (PPM) for people with non-muscle invasive bladder cancer that has come back or not responded to standard therapy. PPM is a nanoparticle designed to deliver chemotherapy directly to tumor ce…

This study tests a new approach to treat high-risk bladder cancer without removing the bladder. Doctors will first remove the tumor through the urethra, then freeze the tumor base with a special balloon, followed by immunotherapy and low-dose chemotherapy. The goal is to see if t…

This study tests whether a simple urine test (Bladder EpiCheck) can safely replace some of the invasive cystoscopy procedures used to monitor non-muscle invasive bladder cancer. About 240 adults with low-grade intermediate-risk bladder cancer will be followed to compare quality o…

This study collects video recordings and data from 500 patients undergoing blue light cystoscopy, a procedure where a drug makes cancer cells glow. The goal is to train an artificial intelligence (AI) algorithm to detect bladder lesions in real time, helping doctors make more acc…

This study looks at whether a simple urine test for tumor DNA can tell which bladder cancer patients truly need a second surgery after their first tumor removal. About 196 adults with non-muscle-invasive bladder cancer will be randomly assigned to have their repeat surgery decisi…

This study is testing whether a simple urine test that looks for cancer DNA can help decide when patients with high-risk bladder cancer need a cystoscopy (a camera exam of the bladder). Cystoscopy is effective but uncomfortable and can cause infections. The goal is to safely redu…

This study looks at whether a simple urine test can detect leftover cancer after initial surgery for high-risk bladder cancer. The goal is to help doctors decide who truly needs a second surgery, avoiding unnecessary procedures and their risks. About 60 adults with high-risk non-…

This study tests whether adding Hydeal Cyst® instillations can reduce lower urinary tract symptoms in people receiving standard chemotherapy or immunotherapy for non-muscle invasive bladder cancer. About 200 participants will receive either BCG or MMC, and half will also get Hyde…

Researchers in the Netherlands are building a nationwide cohort of adults with high-risk non-muscle-invasive, muscle-invasive, and metastatic bladder cancer. The study follows participants over time to measure overall survival, progression-free survival, recurrence-free survival,…

This study is testing whether an artificial intelligence (AI) tool can analyze digital images of bladder tumor tissue to predict how well patients will respond to standard treatments like BCG therapy or chemotherapy. The research involves 600 people with intermediate or high-risk…

This study is collecting blood, urine, and tumor tissue samples from about 400 adults with suspected high-risk non-muscle invasive bladder cancer. The goal is to find biological markers that could lead to new tests for detecting and monitoring this type of cancer. Participants wi…